{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105029","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.497195+00:00","generated_at":"2026-05-17T17:38:25.535202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development","bullets":["Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.","Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.","Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.","Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105029","json":"https://secwatch.observer/filing/0000950170-25-105029.json","markdown":"https://secwatch.observer/filing/0000950170-25-105029.md","text":"https://secwatch.observer/filing/0000950170-25-105029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/0000950170-25-105029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:38:25.535202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}